Rhelion Life Sciences has appointed Samiuddin Khaja as its new Chief Financial Officer, marking a key leadership change as the company focuses on pharmaceutical drug development in the psychedelic sector. Khaja brings over 15 years of global finance experience, including in the psychedelic industry, supporting Rhelion's evolution following its acquisition of Filament Health. The company is now emphasizing research, manufacturing, and regulated supply of psychedelic drug candidates, backed by a strong patent portfolio and clinical trial infrastructure. This leadership update aligns with Rhelion's strategic shift toward becoming a research-led life sciences company.
Mortgage REITs Two Harbors Investment (TWO), Cherry Hill Mortgage Investment (CHMI), and Invesco Mortgage Capital (IVR) each face different futures despite being lumped together by income investors. TWO is winding down through a merger with CrossCoun...
Angkor Resources has completed the first phase of its diamond drilling program at the Andong Bor copper-gold target in Cambodia, finishing 1,099 meters out of a planned 2,800 meters. The initial drilling encountered promising porphyry and skarn miner...
Instacart and Foot Locker have partnered to offer customers nationwide access to Foot Locker, Kids Foot Locker, and Champs Sports products through the Instacart Marketplace. Shoppers can now get footwear, apparel, and accessories delivered in as fast...
Stakeholder Gold Corp announced initial assay results from drill hole BA2601 at its Ballarat Gold-Copper Project in Yukon, Canada. The hole intersected significant copper-nickel-cobalt sulphide mineralization, including a 6-meter zone grading 1,190 p...
Kyndryl received the 2026 CIO 100 Award for its AI-powered change risk prediction feature in Kyndryl Bridge, which helps predict and prevent technology change risks before they cause service outages. This patented innovation combines AI, automation, ...
